Abstract
Introduction: Casirivimab-imdevimab, an antibody cocktail containing two severe acute respiratory syndrome coronavirus 2 neutralizing antibodies, reduces the viral load and the risk of coronavirus disease 2019 (COVID-19)-related hospitalization or death. The objective of this study was to evaluate the clinical efficacy of casirivimab-imdevimab in patients with COVID-19 Delta variant in Japan.
Methods: This study was conducted at five institutions and assessed a total of 461 patients with COVID-19 who met the inclusion criteria. The treatment group received a dose of casirivimab-imdevimab consisting of a cocktail of two monoclonal antibodies, (casirivimab 600 mg and imdevimab 600 mg intravenously). The control consisted of age- and sex-matched COVID-19 patients (n = 461) who sufficed the inclusion criteria but did not receive casirivimab-imdevimab. The outcome was the requirement of oxygen therapy.
Results: In the treatment group, patients received oxygen therapy (n = 30), nasal canula (n = 23), high flow nasal cannula (n = 5), and mechanical ventilation (n = 2). In the control group, patients received oxygen therapy (n = 56), nasal canula (n = 45), high flow nasal cannula (n = 8), and mechanical ventilation (n = 3). The administration of oxygen therapy was significantly lower in the treatment group than the control group (6.5% vs. 12.1%, P = 0.0044). All these patients admitted to our hospitals and received additional therapy and recovered.
Conclusions: Our results demonstrate that the casirivimab-imdevimab combination antibody treatment is associated with reduced rates of requiring oxygen therapy among high-risk patients with COVID-19 Delta variant.
Keywords: COVID-19; Casirivimab-imdevimab treatment; Delta variant; Monoclonal antibody; SARS-CoV-2.
【저자키워드】 COVID-19, SARS-CoV-2, monoclonal antibody, delta variant, Casirivimab-imdevimab treatment, 【초록키워드】 coronavirus disease, SARS-CoV-2, Coronavirus disease 2019, coronavirus, therapy, mechanical ventilation, Hospitalization, Neutralizing antibodies, hospital, monoclonal antibody, Delta, risk, oxygen, nasal, outcome, delta variant, monoclonal antibodies, Viral, antibody cocktail, Viral load, Casirivimab, Imdevimab, Patient, death, Oxygen therapy, Japan, age, respiratory, High-risk patients, antibody treatment, cocktail, Combination, Clinical efficacy, administration, dose, COVID-19 patient, High flow nasal cannula, nasal cannula, acute respiratory syndrome, control group, acute respiratory syndrome coronavirus 2, inclusion criteria, treatment group, intravenously, significantly lower, high-risk patient, FIVE, evaluate, conducted, reduced, reduce, receive, patients with COVID-19, with COVID-19, 【제목키워드】 Treatment, Efficacy, clinical, antibody combination, patients with COVID-19,